not vested
Analysis:
SISRAM MED(1696) is principally engaged in the design, development, manufacture and sale of energy-based aesthetic medical and minimally invasive treatment system.
The Group is focusing on three major hot spots : body contouring, dermatology (skin rejuvenation in specific) and feminine health.
It started in 2018 implementing its " Go East" strategy, delivering the best of the west to the east by utilizing its technological and operational strengths as an industry leader.
For the six months ended 30 June 2018, the Group`s revenue increased 17.9% to US$78.2 million as compared to the corresponding period in 2017 and net profit attributable to shareholders increased 43.9% to US$11.3 million.(I do not hold the above stock)
Strategy:
Buy-in Price: $4.80, Target Price: $5.50, Cut Loss Price: $4.45
Source: Phillips